Currently, TKIs, which are potent inhibitors of Bcr-Abl protein kinases, c-Kit and the platelet-derived growth factor receptor (Valk-Lingbeek et al., 2004; Slupianek et al., 2013), are widely used for treatment of CML due to their highly efficient control of CML at chronic phase. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.